The Italian pharmaceutical industry continues to set new records, fueled by exports that now account for more than 10% of total Italian industrial exports. This is also due to the "magnificent 13" of Made in Italy pharmaceuticals: the 13 main Italian-owned companies—the so-called "Fab13"—that, along with a large group of subcontractors and numerous multinational groups operating in the country, drive this excellence, which is now an Italian asset reaching the entire world. Exports were €19.2 billion in 2019, rising to €53.8 billion in 2024 and potentially exceeding €70 billion by 2025. Pharmaceuticals outpaced iconic Made in Italy products, including wines, sports cars, and shipbuilding, in terms of foreign trade during the first nine months of last year. The results are even more significant among the Fab 13, where collective revenues increased 12% in 2024 to €18.9 billion (up from €12.7 billion just three years ago). The foreign component increased by 14%, whereas the domestic market expanded by only 2% due to stagnating domestic demand. The Fab13 are Alfasigma, Abiogen Pharma, Angelini Pharma, Chiesi Farmaceutici, Dompé Farmaceutici, I.B.N. Savio, Italfarmaco, Kedrion, Menarini, Molteni, Neopharmed Gentili, Recordati, and Zambon.